Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders

Eligibility Criteria

• 1. are 18 years or older
• 2. have a chart DSM V diagnosis of schizophrenia spectrum or schizoaffective or bipolar disorder or any other mental illness disorder
• 3. have received ACM and antipsychotic medications for 6 months or more
• 4. are considered to be clinically stable (by the patient's healthcare team) for 3 months or more
• 5. the ACM (e.g. benztropine and/or trihexyphenidyl) is being used to treat EPS associated with antipsychotic medications.
• 6. on an examination using the modified Simpson-Angus Extrapyramidal Symptoms Scale (head dropping and leg pendulousness items are dropped), no single item rated at 3 or 4.
• 7. able and willing to sign the approved informed consent document.
• 1. patients with ongoing Parkinsonian symptoms who require ACM meds for countering EPS side effects based on the Simpson-Angus Scale score cutoffs.
• 2. if the clinicians treating the potentially eligible patients consider them to be clinically unstable or if drug-addiction is the focus of treatment and participation in ACM de-prescription protocols is considered risky, the team will defer to the treating clinicians to exclude participants.
• 3. The same exclusions will apply to those persons undergoing medical procedures and treatments that make participation in this ACM deprescription trial unwise per the treating team.